Mark Rothera
Directeur Général chez VIRACTA THERAPEUTICS, INC.
Fortune : 84 700 $ au 30/04/2024
Profil
Mark A.
Rothera is currently the President, Chief Executive Officer & Director at Viracta Therapeutics, Inc. He is also a Director at Genpharm Services, President & Director at Orchard Therapeutics North America, and a Director at NAYA Biosciences.
Previously, he served as the President, CEO & Executive Director at Silence Therapeutics Plc, President, Chief Executive Officer & Director at Orchard Therapeutics (Europe) Ltd., and President, CEO & Executive Director at Orchard Therapeutics Plc.
He was also the Chief Commercial Officer at PTC Therapeutics, Inc., Executive VP-Strategy & Business Development at Aegerion Pharmaceuticals, Inc., and President & General Manager-Commercial Operations at Shire Human Genetic Therapies, Inc. Additionally, he was the Vice President-Europe, Middle East & Africa at CHIRON Biopharmaceuticals.
Mr. Rothera holds a graduate degree from the University of Cambridge and an MBA from INSEAD.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/03/2024 | 100 000 ( 0,25% ) | 84 700 $ | 30/04/2024 |
Postes actifs de Mark Rothera
| Sociétés | Poste | Début |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Directeur Général | 19/09/2022 |
Genpharm Services
 Genpharm Services Advertising/Marketing ServicesCommercial Services Genpharm Services operates as a pharmaceutical company providing partners with market access and commercial solutions into the Middle East and North Africa region. It also acts as a commercial partner for rare genetic diseases, orphan drugs, and specialty therapeutics and offers strategic advice on disease areas, product launches and go-to markets strategies. The company was founded by Karim Smaira and Kamel Ghammachi in 2012 and is headquartered in Dubai, United Arab Emirates. | Directeur/Membre du Conseil | - |
Orchard Therapeutics North America
 Orchard Therapeutics North America BiotechnologyHealth Technology Part of Orchard Therapeutics Plc, Orchard Therapeutics North America provides biotechnology research services. The private company is based in Boston, MA. The CEO of the company is Bobby Gaspar. | President | - |
Anciens postes connus de Mark Rothera
| Sociétés | Poste | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Directeur Général | 21/02/2022 |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Directeur Général | 17/03/2020 |
| ORCHARD THERAPEUTICS PLC | Directeur Général | 17/03/2020 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 09/08/2017 |
| AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2013 |
Formation de Mark Rothera
| University of Cambridge | Graduate Degree |
| INSEAD | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| CHIRON Biopharmaceuticals | |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Genpharm Services
Genpharm Services Advertising/Marketing ServicesCommercial Services Genpharm Services operates as a pharmaceutical company providing partners with market access and commercial solutions into the Middle East and North Africa region. It also acts as a commercial partner for rare genetic diseases, orphan drugs, and specialty therapeutics and offers strategic advice on disease areas, product launches and go-to markets strategies. The company was founded by Karim Smaira and Kamel Ghammachi in 2012 and is headquartered in Dubai, United Arab Emirates. | Commercial Services |
Orchard Therapeutics North America
Orchard Therapeutics North America BiotechnologyHealth Technology Part of Orchard Therapeutics Plc, Orchard Therapeutics North America provides biotechnology research services. The private company is based in Boston, MA. The CEO of the company is Bobby Gaspar. | Health Technology |
